Dr. Reddy's Laboratories Ltd. (RDY)'s Announces the Launch of Lamotrigine Extended-Release Tablets
6/26/2013 11:08:43 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories (NYSE: RDY) announced today that is has launched Lamotrigine Extended-Release Tablets (25 mg, 50 mg, 100 mg, 200 mg, 300 mg) a therapeutic equivalent generic version of Lamictal® XR (lamotrigine) in the US market on June 25, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy’s ANDA for Lamotrigine XR tablets.
Help employers find you! Check out all the jobs and post your resume.
comments powered by